The Motley Fool
21 Jul 2026, 00:08 UTC · 9h ago
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
21 Jul 2026, 00:08 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Corcept Therapeutics raised its full-year revenue guidance to a range between $950 million and $1.05 billion. — An upward revision of revenue guidance is a strong positive signal for growth and immediate stock price appreciation.
+0.60Corcept's drug relacorilant received FDA approval for use in treating ovarian cancer. — Regulatory approval for a new indication expands the addressable market and creates a new revenue stream.
+0.50Director James N. Wilson sold 10,000 shares of Corcept Therapeutics on July 15, 2026. — While insider selling can be a red flag, the small volume relative to his remaining 1.5 million shares suggests it is not a lack of confidence in the company.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company raised full-year revenue guidance and received FDA approval for a drug in ovarian cancer, outweighing the director's share sale.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
8h ago
